Feels amazing to close 2019 with such great news: BioReperia is now officially settled in Switzerland! It has been an incredible year for us, and we are so thrilled to have the support of HemexAG throughout our journey!
Huge thanks to Pascal Winnen and Franziska Stemmler for the support, we look forward to many successes together!
"We are very excited to welcome Swedish startup BioReperia to our fast-growing incubator in Liestal. The Swiss subsidiary will focus on the DACH (Germany, Austria, and Switzerland) region and support the rapid expansion of BioReperia throughout Europe." (Hemex AG)
BioReperia´s technology is based on a proprietary zebrafish screening platform, which will allow to reduce cancer mortality by predicting the most efficient treatment for individual patients within 5 days, and to accelerate drug development for the pharmaceutical industry. The company plans to launch its first CE-certified in vitro diagnostic (IVD) product Zebrafish Tumor Xenograft (ZTX®)-PREDICT for bladder cancer by 2021. The unique ZTX® platform is already on the market as a research service, helping drug development companies accelerate their drug candidate discovery process.
Prof. Dr. Anna Fahlgren, CEO of BioReperia AB, commented: “After our successful Series A funding round earlier this year, the company has made significant steps towards market approval for our first precision medicine product. Our next goal is to continue our clinical validation program and to start clinical trials in Switzerland in the first half of 2020”.
BioReperia AB is a Swedish biotech company with the vision to reduce cancer mortality by identifying the most efficient treatment for each cancer patient and improve the cost effectiveness of modern anticancer therapies. BioReperia was founded by Anna Fahlgren and Lasse Jensen in 2015 and is located at Linköping’s University. The founders have more than 10 years’ experience developing and using zebrafish models for medical research including toxicology and tumor biology. BioReperia’s zebrafish models are today widely used in both academic and industrial research to accelerate drug discovery.
Read more at our LinkedIn page.
HEMEX AG is a privately-owned swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding.